Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ARTV 
Artiva Biotherapeutics, Inc. Common Stock (ARTV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: ARTV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.4
1 Year Target Price $16.4
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.02% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 92.09M USD | Price to earnings Ratio - | 1Y Target Price 16.4 |
Price to earnings Ratio - | 1Y Target Price 16.4 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 1.47 - 15.49 | Updated Date 11/4/2025 |
52 Weeks Range 1.47 - 15.49 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -41.57% | Return on Equity (TTM) -86.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -57085003 | Price to Sales(TTM) 214.51 |
Enterprise Value -57085003 | Price to Sales(TTM) 214.51 | ||
Enterprise Value to Revenue 7.54 | Enterprise Value to EBITDA - | Shares Outstanding 24425762 | Shares Floating 5407131 |
Shares Outstanding 24425762 | Shares Floating 5407131 | ||
Percent Insiders 19.88 | Percent Institutions 75.79 |
Upturn AI SWOT
Artiva Biotherapeutics, Inc. Common Stock
Company Overview
History and Background
Artiva Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing off-the-shelf, allogeneic natural killer (NK) cell therapies for the treatment of cancer. Founded in 2019, Artiva leverages its AlloNK platform to advance a pipeline of NK cell therapies designed to be readily available and accessible to patients. They have advanced rapidly through pre-clinical and into clinical trials, fueled by investor interest in novel cancer therapies.
Core Business Areas
- AlloNK Cell Therapy Development: Developing and manufacturing off-the-shelf, allogeneic natural killer (NK) cell therapies.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their NK cell therapies in various cancer indications.
- Manufacturing and Supply Chain: Establishing a robust manufacturing process and supply chain for the production and distribution of AlloNK cells.
- Partnerships and Collaborations: Establishing partnerships to further development of NK cell therapies.
Leadership and Structure
Peter Flynn serves as the President and CEO. The company has a board of directors with expertise in biopharmaceuticals and venture capital. The organizational structure is typical of a clinical-stage biotech, emphasizing research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- AB-101: AB-101 is Artiva's lead product candidate, an off-the-shelf, cryopreserved, allogeneic NK cell therapy designed to enhance the activity of antibody-dependent cellular cytotoxicity (ADCC) in combination with monoclonal antibodies or other cancer therapies. Market share data is not yet available as it is still in clinical trials. Competitors include companies developing similar NK cell therapies such as Fate Therapeutics and Nkarta.
- AB-201: AB-201 is an armored AlloNK cell therapy designed to enhance antitumor activity in solid tumors. Still in preclinical stages. Market share data is not yet available. Competitors are similar to AB-101.
Market Dynamics
Industry Overview
The cell therapy market, particularly for cancer treatment, is experiencing significant growth driven by advancements in immunotherapy and personalized medicine. There's a high demand for off-the-shelf, scalable therapies like NK cell therapies, offering an alternative to autologous CAR-T cell therapies.
Positioning
Artiva is positioned as a key player in the allogeneic NK cell therapy space, aiming to provide readily available and cost-effective treatments compared to autologous therapies. Their AlloNK platform distinguishes them through its scalability and potential for broad patient access.
Total Addressable Market (TAM)
The TAM for cell therapies in oncology is estimated to reach billions of dollars. Artiva is targeting a portion of this market by focusing on indications where NK cell therapies can provide a significant clinical benefit, competing with other allogeneic and autologous cell therapy companies.
Upturn SWOT Analysis
Strengths
- AlloNK platform offering scalability and potential cost advantages.
- Focus on off-the-shelf therapies for broad patient access.
- Experienced management team.
- Strong intellectual property position.
Weaknesses
- Clinical-stage company with no approved products.
- Reliance on successful clinical trial outcomes.
- Limited financial resources compared to larger pharmaceutical companies.
- Requires substantial funding to support ongoing research and development.
Opportunities
- Expansion into new cancer indications.
- Partnerships with pharmaceutical companies for combination therapies.
- Advancements in NK cell engineering and manufacturing.
- Positive clinical trial results leading to regulatory approval.
Threats
- Competition from other cell therapy companies.
- Clinical trial failures.
- Regulatory hurdles.
- Manufacturing challenges.
- Financial market volatility affecting funding.
Competitors and Market Share
Key Competitors
- NKTA
- FTAI
Competitive Landscape
Artiva faces competition from other companies developing NK cell therapies, CAR-T cell therapies, and other immuno-oncology approaches. Their AlloNK platform offers a potential advantage in terms of scalability and cost.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the advancement of its clinical pipeline and expansion of partnerships.
Future Projections: Future growth depends on successful clinical trial results and regulatory approvals. Analyst estimates vary based on the perceived probability of success of its clinical programs.
Recent Initiatives: Recent initiatives include progressing AB-101 and AB-201 through clinical trials, expanding manufacturing capabilities, and forming collaborations with other companies.
Summary
Artiva Biotherapeutics is a clinical-stage biotech company focused on allogeneic NK cell therapies. Its AlloNK platform provides potential advantages in scalability and cost. Success hinges on positive clinical trial outcomes, requiring constant monitoring and financial stability. Competition is high in the cell therapy space and regulatory hurdles can be obstacles.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share data are estimates based on available public information and may not be precise. Data subject to change based on new information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Artiva Biotherapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2024-07-19 | President, CEO & Director Dr. Fred Aslan M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 105 | Website https://www.artivabio.com |
Full time employees 105 | Website https://www.artivabio.com | ||
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.